1vsn: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 5: Line 5:
|SITE=  
|SITE=  
|LIGAND= <scene name='pdbligand=NFT:N-(2-AMINOETHYL)-N~2~-{(1S)-1-[4&#39;-(AMINOSULFONYL)BIPHENYL-4-YL]-2,2,2-TRIFLUOROETHYL}-L-LEUCINAMIDE'>NFT</scene>
|LIGAND= <scene name='pdbligand=NFT:N-(2-AMINOETHYL)-N~2~-{(1S)-1-[4&#39;-(AMINOSULFONYL)BIPHENYL-4-YL]-2,2,2-TRIFLUOROETHYL}-L-LEUCINAMIDE'>NFT</scene>
|ACTIVITY= [http://en.wikipedia.org/wiki/Cathepsin_K Cathepsin K], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.22.38 3.4.22.38]  
|ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Cathepsin_K Cathepsin K], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.22.38 3.4.22.38] </span>
|GENE= CTSK, CTSO, CTSO2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])
|GENE= CTSK, CTSO, CTSO2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])
|DOMAIN=
|RELATEDENTRY=
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1vsn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1vsn OCA], [http://www.ebi.ac.uk/pdbsum/1vsn PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1vsn RCSB]</span>
}}
}}


Line 14: Line 17:
==Overview==
==Overview==
Based on our previous study with trifluoroethylamine as a P2-P3 amide isostere of cathepsin K inhibitor, further optimization led to identification of compound 22 (L-873724) as a potent and selective non-basic cathepsin K inhibitor. This compound showed excellent pharmacokinetics and efficacy in an ovariectomized (OVX) rhesus monkey model. The volumes of distribution close to unity were consistent with this compound not being lysosomotropic, which is a characteristic of basic cathepsin K inhibitors.
Based on our previous study with trifluoroethylamine as a P2-P3 amide isostere of cathepsin K inhibitor, further optimization led to identification of compound 22 (L-873724) as a potent and selective non-basic cathepsin K inhibitor. This compound showed excellent pharmacokinetics and efficacy in an ovariectomized (OVX) rhesus monkey model. The volumes of distribution close to unity were consistent with this compound not being lysosomotropic, which is a characteristic of basic cathepsin K inhibitors.
==Disease==
Known disease associated with this structure: Pycnodysostosis OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601105 601105]]


==About this Structure==
==About this Structure==
Line 27: Line 27:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: McGrath, M.]]
[[Category: McGrath, M.]]
[[Category: NFT]]
[[Category: osteoporosis]]
[[Category: osteoporosis]]
[[Category: proteae]]
[[Category: proteae]]
[[Category: structure-guided drug design]]
[[Category: structure-guided drug design]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 23 14:02:15 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 00:28:12 2008''